NABL Accredited · Batch Release Testing

Pharmaceutical Finished Product Testing India | NABL Accredited

Complete quality testing for pharmaceutical finished dosage forms from an NABL-accredited laboratory in India.

Pharmaceutical finished product testing is the final quality verification before a drug product reaches patients. Auriga Research provides NABL-accredited finished product testing services for all dosage forms — tablets, capsules, oral liquids, topicals, injectables, ophthalmics, and inhalation products. Our testing covers the complete pharmacopoeial specification including identity, assay, dissolution, content uniformity, related substances, microbial quality, and dosage-form-specific parameters.

For solid oral dosage forms, our testing includes hardness, friability, disintegration, dissolution profiling (USP apparatus I and II), uniformity of dosage units, and stability-indicating assay and impurity methods. For parenteral products, we perform sterility testing, bacterial endotoxin testing, particulate matter, pH, osmolality, and container closure integrity assessments. Topical products are evaluated for content uniformity, pH, viscosity, and in vitro release testing.

We support both one-time product testing and ongoing batch release programmes with scheduled turnaround commitments. All reports include certificate of analysis with raw data traceability, pharmacopoeial compliance statements, and electronic delivery for seamless integration with your quality management system.

Finished Product Testing by Dosage Form

  • Tablets — hardness, friability, disintegration, dissolution, assay, content uniformity, related substances
  • Capsules — disintegration, dissolution, assay, content uniformity, moisture content
  • Oral liquids — assay, pH, viscosity, specific gravity, preservative content, microbial limits
  • Injectables — sterility, BET, particulate matter, pH, osmolality, assay, related substances
  • Topicals — assay, content uniformity, pH, viscosity, homogeneity, IVRT
  • Ophthalmic preparations — sterility, particulate matter, pH, osmolality, preservative efficacy
  • Inhalation products — delivered dose uniformity, aerodynamic particle size distribution

Turnaround Time

Standard Testing: 7-10 business days
Rush Testing: 3-5 business days
Sterile Product Testing: 14-21 business days
Batch Release Programme: Custom schedule

Frequently Asked Questions — Finished Product Testing

What tests are included in pharmaceutical finished product testing?
Finished product testing varies by dosage form but typically includes description and appearance, identification, assay, dissolution or disintegration, content uniformity, related substances, moisture content, microbial limits, and any dosage-form-specific tests such as hardness and friability for tablets, pH and viscosity for liquids, or sterility and endotoxins for injectables. All testing follows pharmacopoeial monographs or validated in-house methods.
What dosage forms can Auriga test?
Auriga Research tests all pharmaceutical dosage forms including tablets, capsules, oral liquids (syrups, suspensions, solutions), topical preparations (creams, ointments, gels, lotions), parenteral products (injections, infusions), ophthalmic preparations, inhalation products, suppositories, and transdermal patches. Each dosage form has specific test requirements defined by pharmacopoeial monographs and regulatory guidelines.
What is the turnaround time for finished product testing?
Standard finished product testing at Auriga Research is completed within 7-10 business days for routine dosage forms. Rush testing is available within 3-5 business days. Sterile product testing (sterility + BET) requires 14-21 business days due to incubation requirements. Batch release programmes can be customised for faster turnaround.

Need Finished Product Testing for Your Drug Products?

NABL-accredited testing for all dosage forms with 7-10 day turnaround. Batch release programmes and certificate of analysis generation.

Call Now Get a Quote

Type to search services, tests, and locations…